Product Information
CEFTRIAXONE 250 MG VIAL is a generic product labeled by Sandoz Inc., priced at $1.2533 per EA under NDC 00781320685. Its NADAC has been published 343 times since Nov 28, 2013.
FDA first approved this application on May 9, 2005. Its Orange Book therapeutic-equivalence code is AP.
Strength
250 mg/1
Manufacturer
Sandoz Inc.NDC
00781320685
Classification
Generic
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
2/19/2025
Active Ingredients
CEFTRIAXONE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA065169FDA Approved
5/9/2005
TE Code
AP
On Market Since
5/9/2005
Pharmacological Classes
Price Statistics
The NADAC for CEFTRIAXONE 250 MG VIAL has been published 343 times since Nov 28, 2013, and over the history we have for it it has declined 29.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2533 per EA |
|---|---|
| All-time high | $2.1533 (Oct 15, 2014) |
| All-time low | $0.9480 (Jul 17, 2024) |
| 52-week high | $1.2533 |
| 52-week low | $1.2533 |
| Median price | $1.6980 |
| Average price | $1.6571 |
| Largest weekly change | -42.3% (Jul 17, 2024) |
| Weeks tracked | 343 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-23.8%
5Y
-23.8%
All
-29.3%
Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 31% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ceftriaxone Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFTRIAXONE 250 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for CEFTRIAXONE 250 MG VIAL, manufactured by Sandoz Inc., is $1.2533 per EA (NDC 00781320685), effective Feb 11, 2026.
How has the price of CEFTRIAXONE 250 MG VIAL changed over time?
Over the history we have for it, the NADAC for CEFTRIAXONE 250 MG VIAL has declined 29.3%. It has been tracked across 343 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEFTRIAXONE 250 MG VIAL?
Since Nov 28, 2013, the NADAC for CEFTRIAXONE 250 MG VIAL has ranged from a low of $0.9480 (Jul 17, 2024) to a high of $2.1533 (Oct 15, 2014), with a median of $1.6980 per EA.
Are there cheaper alternatives to CEFTRIAXONE 250 MG VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CEFTRIAXONE 250 MG VIAL, is $0.8622 per EA — about 31% below CEFTRIAXONE 250 MG VIAL.
Who manufactures CEFTRIAXONE 250 MG VIAL?
CEFTRIAXONE 250 MG VIAL (NDC 00781320685) is labeled by Sandoz Inc., and CMS classifies it as a generic product.